Related Experiment Videos
Microbiology, pharmacology, and clinical use of mezlocillin sodium
Abstract:
The acylureido penicillin mezlocillin is active against gram-positive, gram-negative, and anaerobic bacteria. It easily penetrates the outer membrane of gram-negative bacteria, and it has a strong affinity for penicillin binding protein 3. Its stability to beta-lactamases is weak. Mezlocillin is synergistic when given in combination with aminoglycoside antibiotics. In pharmacokinetic studies mezlocillin conforms to a two compartment open model; its pharmacokinetic properties are dose-dependent. The half-life of the drug is about 1 hour after intravenous injection and 1.5 hours after intramuscular injection. Protein binding ranges from 16 to 42%, and 55% of a dose is excreted in the urine. Biliary excretion ranges from 0.5 to 25%. Clinical trial cure rates were as follows: bacteremia (78%), respiratory tract (62%), urinary tract (81%), gynecological (86%), bone and joint (55%), intraabdominal (67%) and skin and soft tissue (59%). The frequency of adverse reactions was 7.7%. Interstitial nephritis, CNS toxicity, and bleeding have not been reported.
Insights
Mezlocillin, an acylureido penicillin, effectively treats various bacterial infections, including gram-negative and anaerobic types. Clinical trials show high cure rates across multiple infection sites with a low adverse reaction rate.
Area of Science:
- Pharmacology
- Microbiology
- Clinical Medicine
Background:
- Mezlocillin is an acylureido penicillin antibiotic with broad-spectrum activity.
- It demonstrates efficacy against gram-positive, gram-negative, and anaerobic bacteria.
- Its mechanism involves penetration of the gram-negative outer membrane and affinity for penicillin binding protein 3.
Purpose of the Study:
- To evaluate the pharmacokinetic properties of mezlocillin.
- To assess the clinical efficacy and adverse reaction profile of mezlocillin in treating various infections.
Main Methods:
- Pharmacokinetic studies utilizing a two-compartment open model.
- Clinical trials assessing cure rates across different infection types (bacteremia, respiratory, urinary, gynecological, bone/joint, intraabdominal, skin/soft tissue).
- Monitoring of adverse reactions.
Main Results:
- Mezlocillin exhibits dose-dependent pharmacokinetics with a half-life of approximately 1-1.5 hours.
- High cure rates were observed in clinical trials, particularly for gynecological (86%) and urinary tract (81%) infections.
- The overall frequency of adverse reactions was 7.7%, with no reported cases of interstitial nephritis, CNS toxicity, or bleeding.
Conclusions:
- Mezlocillin is an effective antibiotic with a favorable safety profile for treating a range of bacterial infections.
- Its pharmacokinetic properties and demonstrated clinical efficacy support its use in therapeutic settings.
- Synergistic effects observed with aminoglycoside antibiotics suggest potential for combination therapy.